# Efficacy and Safety of Risperidone and Trazodone Monotherapy and Combination Therapy in Critically Ill Patients With Delirium

> **NCT02118688** · PHASE4 · WITHDRAWN · sponsor: **Rochester General Hospital**

## Conditions studied

- Delirium
- Agitation

## Interventions

- **DRUG:** Risperidone
- **DRUG:** Trazodone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02118688
- **Lead sponsor:** Rochester General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-03
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of enrollment
- **Last updated:** 2019-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02118688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02118688, "Efficacy and Safety of Risperidone and Trazodone Monotherapy and Combination Therapy in Critically Ill Patients With Delirium". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02118688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*